| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. |
| |
|
| This week's sponsor is FierceBiotech. | | | FierceBiotech Presents:
A Half Day Executive Summit
Hosted at the Royal Society of Medicine, London
R&D Challenges: A UK Perspective
Cocktail Reception to follow
27 October, 2016
Register Now! |
Top Stories Of The Week Thursday, October 6, 2016 Pfizer plans to unload its aging Manhattan headquarters, home base since 1961, and move to more up-to-date offices elsewhere in the city. The company hasn’t yet chosen a new base, but like its Big Pharma fellows, it’s clearly looking for an upgrade. More from FiercePharma Thursday, October 6, 2016 When Theranos CEO Elizabeth Holmes presented a new device at a conference this summer, it seemed to be a bid to distract from the company’s much-criticized blood-testing tech. Now, Theranos is abandoning its fingerprick blood tests entirely so it can focus on its new tabletop blood-testing system. More from FierceMedicalDevices Saturday, October 1, 2016 Next-gen psoriasis drugmakers have long been going after Johnson & Johnson’s Stelara, showing they could top the heavyweight with their own up-and-comers in head-to-head studies. Now, though, it’s J&J’s turn to tout data for its own new-age candidate, guselkumab, against another behemoth in the field. More from FiercePharmaMarketing Tuesday, October 4, 2016 The world’s largest CRO and one of the biggest healthcare data and consulting firms have become one major $19 billion 50,000-strong company this week as QuintilesIMS comes into life. More from FierceCRO Tuesday, October 4, 2016 The ax is likely to begin falling at Pfizer’s Rocky Mount, NC, facility in the coming days as the pharma giant begins to trim its workforce there by about 400. More from FiercePharmaManufacturing Tuesday, October 4, 2016 UT Southwestern researchers have removed a protein from the brains of mice with no harmful effects, suggesting that potential Alzheimer’s drugs targeting this protein could do so without affecting memory and learning. More from FierceBiotechResearch Wednesday, October 5, 2016 Novartis will shut down an R&D facility in China and move a second from Singapore to the U.S. as part of a wide-ranging revamp of its research base. More from FiercePharmaAsia Saturday, October 1, 2016 AstraZeneca has named David Goldstein as chief adviser to its new genome sequencing drive. The appointment gives a professor known for his work on genetic drivers of responses to hepatitis C drugs and inherited disorders influence over the direction of AstraZeneca’s move to build and make use of a database of 2 million whole genomes. More from FierceBiotechIT Tuesday, October 4, 2016 Though still years out, an effective Zika vaccine could beat a path to blockbuster sales, thanks to demand from travelers to endemic areas--which include some common tourist destinations. That's a key difference from the limited market prospects in other mosquito-borne diseases. That blockbuster potential, plus an urgent medical need, has prompted a burst of R&D in the field. More from FierceVaccines Monday, October 3, 2016 Bayer is teaming up with Finland's DelSiTech to develop eye drugs on its drug delivery platform, in another move to gain an edge in the increasingly competitive eye-treatment field. More from FierceDrugDelivery Wednesday, October 5, 2016 Eli Lilly rocketed into the No. 3 spot among the world’s top animal health companies when it picked up Novartis Animal Health for $5.4 billion last year--and now it’s set to strengthen its position even more. The company’s Elanco division will acquire Boehringer Ingelheim’s dog and cat vaccines, along with a manufacturing and R&D site in Fort Dodge, Iowa, for $885 million. More from FierceAnimalHealth Resources Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented by: Deloitte Are you prepared to implement Identification of Medicinal Product requirements? Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. |
